A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

February 10, 2012

FDA Panel: Qutenza Pain Patch for Neuropathy Not Ready for Approval

A U.S. Food and Drug Administration advisory committee voted unanimously against recommending the approval of a novel patch applied to the soles of the feet to remedy pain associated with neuropathy in people living with HIV. Though the patch is commercially available for the treatment of shingles-related neuropathy pain, the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee’s review of two clinical trials of the Qutenza capsaicin patch involving HIV-positive volunteers did not find “substantial evidence of effectiveness.”

Based on the data submitted by the drug’s manufacturer, San Mateo, California–based NeurogesX, the advisory committee also concluded that the benefits of Qutenza patch applications did not necessary outweigh the risks of treatment and therefore it was not acceptable for an approval.

Though the FDA is not required to follow the guidance of its independent advisory committees, it usually does so. In a pre-advisory committee briefing document, released February 7, the agency’s division of anesthesia, analgesia and addiction products expressed reservations about approving Qutenza. “It would not be in the best interest of these patients for us to approve a product for which substantial evidence of efficacy has not been demonstrated, or one for which the benefits do not clearly outweigh the risks,” the document reads.

“We will continue to work closely with the FDA to address the advisory committee’s comments as the Agency finalizes its review of our [application],” said Ronald Martell, president of NeurogesX, in a brief announcement released by the company. “We remain confident that Qutenza has the potential to address significant, unmet medical needs and to improve the quality of life for patients with HIV-[associated peripheral neuropathy].”

In light of the conflicting data from the two studies reviewed by the FDA, advisory committee members suggested that a third study be conducted to either confirm or refute Qutenza’s efficacy. It is not clear whether NeurogesX can commit to such a study.

The FDA has until March 7, 2012, to determine whether or not to expand Qutenza’s approved usages to include HIV-associated peripheral neuropathy. Though people suffering from HIV-associated peripheral neuropathy may still be able to access the patch “off label,” many public and private health insurance plans require FDA approval supporting specific use of a drug in their coverage determinations.

The Qutenza patch—it contains 8 percent capsaicin, a high concentration of the chemical that gives chili peppers their pungency—was approved in the United States in November 2009 for the treatment of neuropathic pain associated with postherpetic neuralgia, and it has been approved in the European Union for the treatment of peripheral neuropathic pain in nondiabetic adults.

Search: Qutenza, capsaicin, neurogesx, patch, neuropathy, FDA, advisory committee, approval, vote, efficacy, safety


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    chipper52
    Palm Springs
    California


    zeze42
    Bay Area - Peninsula
    California


    youngbloodlatino
    Columbia
    Maryland


    humboman
    Baltimore
    Maryland
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.